Mankind Pharma: Morgan Stanley on Mankind Pharma Overweight (Initiated), Target Price Rs 2500 as 11% revenue CAGR, ~25% EPS CAGR, domestic recovery, Bharat Serums and Vaccines optionality and 11–12% IPM growth drive superior risk-reward.

 27 Mar 2026 09:03 AM

Mankind Pharma: Morgan Stanley on Mankind Pharma Overweight (Initiated), Target Price Rs 2500 as 11% revenue CAGR, ~25% EPS CAGR, domestic recovery, Bharat Serums and Vaccines optionality and 11–12% IPM growth drive superior risk-reward.

Mankind Pharma: Purchases Rivotril Brand in India To Boost CNS Treatments; Gains Exclusive Rights For Production, Sales, And Distribution; Enhances Options For Neurological Care.

 18 Mar 2026 10:02 AM

Mankind Pharma: Purchases Rivotril Brand in India To Boost CNS Treatments; Gains Exclusive Rights For Production, Sales, And Distribution; Enhances Options For Neurological Care.

Mankind Pharma: Search And Seizure/Inspection Operation Conducted By Gst Department At Bharat Serums And Vaccines || Unit Operations Continued As Usual During Inspection

 09 Feb 2026 03:04 PM

Mankind Pharma: Search And Seizure/Inspection Operation Conducted By Gst Department At Bharat Serums And Vaccines || Unit Operations Continued As Usual During Inspection

MANKIND PHARMA: OPERATION CONDUCTED FROM FEBRUARY 03 TO FEBRUARY 08, 2026 || BUSINESS OPERATIONS OF BSV CONTINUED AS USUAL DURING SEARCH

 09 Feb 2026 03:05 PM

MANKIND PHARMA: OPERATION CONDUCTED FROM FEBRUARY 03 TO FEBRUARY 08, 2026 || BUSINESS OPERATIONS OF BSV CONTINUED AS USUAL DURING SEARCH

MANKIND PHARMA: Q3 REVENUE 36B RUPEES VS 32B (YOY)

 03 Feb 2026 04:29 PM

MANKIND PHARMA: Q3 REVENUE 36B RUPEES VS 32B (YOY)

MANKIND PHARMA: Q3 EBITDA 9.19B RUPEES VS 8.30B (YOY) || Q3 EBITDA MARGIN 25.76% VS 25.7% (YOY)

 03 Feb 2026 04:29 PM

MANKIND PHARMA: Q3 EBITDA 9.19B RUPEES VS 8.30B (YOY) || Q3 EBITDA MARGIN 25.76% VS 25.7% (YOY)

MANKIND PHARMA: Q3 CONS NET PROFIT 4.1B RUPEES VS 3.8B (YOY); EST 5.1B

 03 Feb 2026 04:29 PM

MANKIND PHARMA: Q3 CONS NET PROFIT 4.1B RUPEES VS 3.8B (YOY); EST 5.1B

Mankind Pharma: Co To Consider Q3 Results On Feb 3

 09 Jan 2026 11:56 AM

Mankind Pharma: Co To Consider Q3 Results On Feb 3